HC Wainwright Reiterates “Buy” Rating for TScan Therapeutics (NASDAQ:TCRX)

Posted by Brenda Bartman on Aug 12th, 2026

TScan Therapeutics (NASDAQ:TCRX – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Wednesday,Benzinga reports.

Several other research analysts have also recently weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 target price on shares of TScan Therapeutics in a research note on Tuesday, June 23rd. Wedbush reiterated an “outperform” rating and issued a $5.00 price target on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a report on Friday, July 17th. Finally, Wall Street Zen lowered shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.00.

Get Our Latest Stock Report on TCRX

TScan Therapeutics Price Performance

TCRX traded down $0.02 during trading on Wednesday, reaching $0.76. The stock had a trading volume of 177,699 shares, compared to its average volume of 703,929. The firm has a market capitalization of $49.47 million, a price-to-earnings ratio of -0.79 and a beta of 1.06. The company has a quick ratio of 6.65, a current ratio of 6.65 and a debt-to-equity ratio of 0.34. TScan Therapeutics has a 1-year low of $0.72 and a 1-year high of $2.57. The stock has a 50 day moving average of $0.91 and a two-hundred day moving average of $1.02.

TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.06. TScan Therapeutics had a negative return on equity of 91.94% and a negative net margin of 1,360.61%.The company had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $1.88 million. As a group, equities analysts anticipate that TScan Therapeutics will post -1.11 EPS for the current fiscal year.

Institutional Investors Weigh In On TScan Therapeutics

Several large investors have recently modified their holdings of the stock. Boothbay Fund Management LLC raised its position in shares of TScan Therapeutics by 50.0% during the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after purchasing an additional 8,121 shares during the period. Panagora Asset Management Inc. acquired a new position in shares of TScan Therapeutics in the 4th quarter valued at $25,000. Landscape Capital Management L.L.C. purchased a new position in TScan Therapeutics in the 2nd quarter worth about $25,000. HRT Financial LP purchased a new position in TScan Therapeutics in the 4th quarter worth about $26,000. Finally, Public Employees Retirement System of Ohio purchased a new position in TScan Therapeutics in the 1st quarter worth about $28,000. 82.83% of the stock is owned by institutional investors.

About TScan Therapeutics

(Get Free Report)

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.